A more complete understanding of the genetic basis of drug resistance in Mycobacterium tuberculosis is critical for prompt diagnosis and optimal treatment, particularly for toxic second-line drugs such as d-cycloserine. Here we used the whole-genome sequences from 498 strains of M. tuberculosis to identify new resistance-conferring genotypes. By combining association and correlated evolution tests with strategies for amplifying signal from rare variants, we found that loss-of-function mutations in ald (Rv2780), encoding l-alanine dehydrogenase, were associated with unexplained drug resistance. Convergent evolution of this loss of function was observed exclusively among multidrug-resistant strains. Drug susceptibility testing established that ald loss of function conferred resistance to d-cycloserine, and susceptibility to the drug was partially restored by complementation of ald. Clinical strains with mutations in ald and alr exhibited increased resistance to d-cycloserine when cultured in vitro. Incorporation of d-cycloserine resistance in novel molecular diagnostics could allow for targeted use of this toxic drug among patients with susceptible infections.
Molecular diagnostic testing has transformed pathogen identification and subsequent drug susceptibility testing (DST) in the field of clinical microbiology 1 . In particular, the recent adaptation of rapid genotypic diagnostics for M. tuberculosis 2, 3 has revolutionized the detection of M. tuberculosis and determination of drug resistance by assaying for the presence of specific resistance-conferring mutations. To minimize morbidity and mortality associated with drug-resistant M. tuberculosis, it is critical to treat patients with antitubercular drugs to which their infecting strains are susceptible 4, 5 and also to prescribe the minimally toxic regimen that is capable of curing the disease 6 . However, current genotypic diagnostics for M. tuberculosis are limited in that they identify only a subset of previously known resistance mutations, and the catalog of mutations that confer resistance is incomplete. For example, the Hain Genotype MTBDRsl test 3 (see URLs) can provide insight into second-line drug resistance in M. tuberculosis strains, but it only interrogates a limited number of resistance mutations and fails to diagnose one in three to four cases of extensively drug-resistant (XDR) tuberculosis (TB) 7 . As many second-line drugs included in regimens for multidrug-resistant (MDR) infections are highly toxic [8] [9] [10] [11] [12] , the incomplete data provided by current molecular tests may result in needless exposure to toxic agents, for example, in the case of rifampicin monoresistance detected by GeneXpert 2 that is treated as MDR.
d-cycloserine is one such highly toxic second-line drug for which potential resistance is not evaluated by current molecular diagnostics. The World Health Organization (WHO) has classified d-cycloserine as a category 4 drug for the treatment of TB, indicating that it is an oral bacteriostatic second-line agent. d-cycloserine remains a cornerstone of MDR and XDR TB treatment, despite severe psychiatric and central nervous system toxicities 9, 10, 12 . With these associated toxicities, it would be ideal to further restrict its use to patients harboring strains that are susceptible to d-cycloserine. Phenotypic DST for d-cycloserine has only been validated on Löwenstein-Jensen (LJ) medium; however, routine phenotypic DST is performed infrequently and is not recommended by the WHO because of technical difficulties with the assay [13] [14] [15] .
Given these difficulties with phenotypic resistance characterization and toxicities, it would be ideal to detect d-cycloserine resistance via rapid molecular diagnostics. However, the molecular basis of d-cycloserine resistance among clinical isolates of M. tuberculosis is poorly understood. d-cycloserine functions by competitively inhibiting two enzymes in the alanine metabolism pathway-alanine racemase (encoded by alr; Rv3423c) 16 and d-alanine-d-alanine ligase (encoded by ddlA; Rv2981c) 17, 18 -which are essential for peptidoglycan synthesis. Overexpression of alr and ddlA has previously been shown to confer resistance to d-cycloserine in Mycobacterium smegmatis 19, 20 , and acquisition of a nonsynonymous mutation in alr in M. tuberculosis was shown to be correlated with the acquisition of phenotypic resistance to d-cycloserine 21, 22 . In addition, Mycobacterium bovis BCG, an attenuated live-vaccine strain derived from M. bovis, is intrinsically resistant to d-cycloserine 23 , a phenotype that is only partially explained by a mutation in cycA (encoding an alanine transporter) 24 . However, to our knowledge, no mutations in M. tuberculosis have been experimentally validated as conferring resistance to d-cycloserine, and there is uncertainty over the critical concentration of the drug that defines resistance.
Recently, whole-genome sequencing has provided more complete information about the genetic content of drug-resistant M. tuberculosis 21, [25] [26] [27] [28] , including in investigations that have used signatures of convergent evolution and positive selection to search for new genes involved in drug resistance 25, 26 . Here we combined two large studies of M. tuberculosis 26, 28 with comparable whole-genome sequencing and phenotypic drug resistance data to identify mutations that associate with drug resistance. These two studies, from South Africa and China, included a total of 498 strains with varying degrees of drug resistance, including large numbers of MDR and XDR strains. By using strategies for amplification of signal from rare variants and by combining an association test with a correlated evolution test, we identified the gene ald (Rv2780), encoding l-alanine dehydrogenase, as a candidate drug-resistance-conferring gene. We then demonstrated that loss of function of ald conferred resistance to d-cycloserine in vitro and that clinical strains with ald loss-of-function mutations were resistant to this drug.
RESULTS

Identification of candidate resistance-conferring variants
We first compiled a data set of 498 strains of M. tuberculosis from South Africa and China, including whole-genome sequencing and phenotypic drug resistance data 26, 28 . We next sought to assess how much unexplained drug resistance was present among these strains by comparing the genomic variants detected in each strain to a list of resistance-associated variants for eight drugs drawn from current diagnostics and the literature ( Supplementary Tables 1 and 2 , and Supplementary Note). The amount of unexplained drug resistance varied by drug, with anywhere between 8 and 21 strains without known resistance-conferring mutations per drug ( Table 1) . Given the limited numbers of strains that were phenotypically resistant but lacked known genotypic resistance mechanisms for individual drugs, we reasoned that new mechanisms of resistance might be rare and difficult to identify statistically on the basis of individual variants. We therefore collapsed the genotypic data using two approaches: first by frequency of variants in the population and second on the basis of the variants' functional impact (Online Methods). Specifically, in the second approach, we collapsed different loss-of-function mutations (each defined as a nonsense mutation, frameshift, or large in-frame insertion or deletion (indel)) within the same gene, as loss of function of select genes is known to confer resistance to specific drugs in M. tuberculosis [29] [30] [31] [32] [33] . Synonymous SNPs were excluded in both approaches. Using these criteria, a combined set of 11,704 genotypic features was generated for downstream analysis.
To identify new resistance-conferring mutations in this data set, we hypothesized that resistance-conferring genotypes should follow two patterns: (i) there should be a positive correlation between the presence of a resistance-conferring mutation and the presence of phenotypic resistance and (ii) a resistance-conferring mutation and phenotypic resistance should evolve convergently and in concert (that is, they should evolve repeatedly and at the same times in evolutionary history). We therefore conducted two tests: a Fisher's exact test to measure the direct association between genotype and phenotype, and a test for correlated evolution 34 of genotype and phenotype. We then combined the P values from both tests into an F score (Online Methods).
Analysis of the combined set of genotypic features with the Fisher's exact and correlated evolution tests for each drug indicated that, in almost all cases, mutations already known to confer drug resistance were the most significant genotypic features, resulting in the highest combined F scores ( Fig. 1 and Supplementary Table 3 ). However, for most drugs, genotypic features known to confer resistance to drugs other than the one being analyzed in the association tests were also often highly significant across both tests, yielding high F scores. For example, mutations in katG, pncA, rpoB, embB, and rpsL were significantly associated with isoniazid resistance despite the fact that katG is the only gene on this list that confers resistance to isoniazid. This finding is due to the fact that the drugs used to treat M. tuberculosis are prescribed only in combination and, therefore, resistances frequently co-occur.
After excluding known resistance-conferring features, the remaining high-scoring features included genes encoding PE-PGRS proteins, polyketide synthases, secretion-associated proteins, and hypothetical proteins ( Supplementary Table 3 ). However, when further examined, none of these other high-scoring features could account for a large fraction of phenotypic resistance in strains without known genotypic resistance mechanisms. Rather, these features most often appeared in strains where phenotypic resistance could already be explained by known resistance-conferring mutations.
Loss of function correlates with unexplained resistance
Given that the list of the highest scoring features contained many genes already associated with resistance and that the remaining high-scoring features co-occurred with known resistance-conferring mutations, we hypothesized that the strong statistical signal contributed by mutations in these genes could make the identification of new, low-frequency resistance mechanisms difficult. To amplify the signal from strains potentially having new resistance genotypes, we repeated the association analysis after The total number of strains assayed for phenotypic resistance to each drug is shown, along with the number of phenotypically resistant (R) and phenotypically susceptible (S) strains. The number of strains with phenotypic drug resistance but without a match to known resistance-associated mutations is given.
A r t i c l e s removing strains with known resistanceconferring mutations ( Supplementary Fig. 1 and Supplementary Table 4 ).
From this analysis, we identified 21 genes with loss-of-function mechanisms that were associated with phenotypic resistance to at least one of nine drugs (excluding PE/PPE genes and transposable elements; Supplementary Tables 4 and 5). Eight of these drug-resistance-associated genes were represented in a library of M. tuberculosis single-gene knockout mutants with gene interruption conferred by a kanamycin resistance cassette 35 . We screened all available knockout mutants representing these eight genes against a panel of five antitubercular drugs (plus the positive control, kanamycin). We observed no resistance above the critical concentration to any of the tested drugs other than kanamycin, indicating that loss of function of each of these genes individually is insufficient to confer resistance to this particular panel of drugs ( Supplementary Table 6 ).
One gene, ald (Rv2780), was notable in that it had an especially high number of unique loss-of-function mutations that appeared to evolve in a pattern consistent with convergent evolution. We identified 11 different ald loss-of-function mutations in 25 South African strains across four different spoligotypes, including 1 nonsense mutation and 10 distinct indels ( Fig. 2a and Supplementary Table 7 ). When examined within a phylogenetic context, ald loss-of-function mutations appeared to evolve exclusively and repeatedly in MDR and XDR genetic backgrounds, suggesting selection for loss of function of this gene among patients receiving second-line drug regimens ( Fig. 2b) . Four other genes had loss-of-function mutations that occurred exclusively within an MDR or XDR genetic background (Rv1250, Rv2042c, Rv3197A (whiB7), and Rv3823c (mmpl8)), although in all cases mutation occurred at a much lower frequency than that in ald (Supplementary Table 5 ). The role of loss-of-function mutations in these genes is unclear, as Rv1250 expression is induced by drug exposure 36 , mmpl8 expression has been positively correlated with virulence 37 , and overexpression of whiB7 has been shown to confer cross-resistance to aminoglycosides 38, 39 , whereas whiB7-null mutants have been shown to be hypersusceptible to multiple antibiotics, including macrolides 40, 41 (Supplementary Note).
ald loss of function confers resistance to d-cycloserine
The ald gene encodes l-alanine dehydrogenase, a component of the alanine metabolism pathway, which includes the targets of the second-line drug d-cycloserine ( Fig. 3) 42 . d-cycloserine resistance was not prospectively phenotypically assayed in the 498 strains analyzed here; however, d-cycloserine and terizidone, a dimeric form of d-cycloserine, are routinely prescribed as part of the South African treatment guidelines for drug-resistant M. tuberculosis 43 . Therefore, MDR and XDR M. tuberculosis strains in this region could have developed d-cycloserine resistance as a result of selective drug pressure.
To investigate whether ald loss of function conferred resistance to d-cycloserine, we determined the minimum inhibitory concentration (MIC) on LJ medium (Online Methods) for four strains: (i) CDC1551, a fully drug-susceptible reference strain of M. tuberculosis (with wild-type alleles of ald, alr, ddlA, and cycA), (ii) an ald knockout strain (∆ald), (iii) the ald knockout complemented with wild-type ald from M. tuberculosis (∆ald-comp), and (iv) M. bovis BCG Danish 1331 (BCG), a strain known to be naturally resistant to d-cycloserine 23, 44 . Testing was repeated in multiple independent experiments to establish the reproducibility of the assay; results are shown in Table 2 . Wild-type M. tuberculosis was the most susceptible to d-cycloserine (MIC = 15 µg/ml), whereas the positive control BCG was the most resistant (MIC = 40-60 µg/ml). The ald knockout strain had greater resistance than the wild-type strain (MIC = 25-30 µg/ml), with the MIC range overlapping the WHOdetermined critical concentration for resistance on LJ medium of 30 µg/ml (ref. 15 ). Complementation with ald partially restored susceptibility to d-cycloserine (MIC = 20 µg/ml). These results demonstrate that, in vitro, ald loss of function confers a moderate level of resistance to d-cycloserine. Figure 1 Significance of associations between genotypic variants and drug resistance phenotypes. Each circle represents a genotypic feature that is plotted at the intersection of the negative log-transformed P values from the Fisher's exact and correlated evolution tests for each drug. P values were corrected for multiple comparisons using the Benjamini-Hochberg method 60 . Genotypic variants known to confer resistance are colored according to the drug to which they confer resistance, and genotypes with no known effect on drug resistance are shown in gray. Genotypes scoring well in both tests appear in the upper right quadrants of the plots.
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A r t i c l e s These results were also confirmed in a growth advantage assay, in which all strains were cultured in a mycobacterial growth indicator tube (MGIT) system with varying concentrations of d-cycloserine (0, 7.5, and 15 µg/ml) and the resulting time to positivity (detectable growth) in the presence of the drug was normalized to the corresponding time for the no-drug control (Fig. 4 , Online Methods, and Supplementary Fig. 2) . The ald knockout strain had a significant growth advantage relative to the wild-type strain at 7.5 µg/ml d-cycloserine (P < 0.0001, ANOVA) and showed no significant growth difference when compared to the resistant control strain, BCG, at the same drug concentration (Fig. 4a) . At a higher concentration of d-cycloserine (15 µg/ml), the ald knockout strain still had a growth advantage relative to the wild-type strain (P < 0.0001, ANOVA; Fig. 4b ) but grew more slowly than BCG (P < 0.0001, ANOVA), supporting the MIC data, which showed that ald loss of function confers less resistance than the mechanism present in BCG. At both drug concentrations, complementation with ald partially reverted the growth advantage conferred by ald knockout (P < 0.0001, ANOVA; Fig. 4a,b) .
Within the M. tuberculosis complex (MTBC), BCG is uniquely considered resistant to d-cycloserine 45 . This resistance was previously shown to be, at least in part, due to a unique SNP in cycA, which encodes an alanine transporter 24, 46 . However, all of the RD9 lineages of the MTBC from Mycobacterium africanum to M. bovis, including BCG, have a frameshift in ald causing loss of function ( Supplementary Fig. 3) 47, 48 . We therefore sought to evaluate the effect of the frameshift in both the BCG strain and the more general RD9 genetic background by determining the MIC of two additional strains: Table 2) , indicating a similar level of resistance to that observed in the ∆ald strain and greater resistance than that observed in the M. tuberculosis reference strain, CDC1551. The ald-complemented BCG strain had an MIC of 40 µg/ml, which was not different from that for the wild-type BCG strain ( Table 2) , although in a growth advantage assay, at 15 and 20 µg/ml d-cycloserine, BCG had a significant growth advantage when compared to the ald-complemented BCG strain (P < 0.02 and P < 0.0001, respectively; Supplementary  Figs. 4 and 5, and Supplementary Note) . Taken together, these results suggest that ald loss of function may both have a minor role in the resistance of BCG to d-cycloserine and provide M. bovis with elevated resistance to d-cycloserine relative to M. tuberculosis.
ald and alr in d-cycloserine-resistant clinical isolates
To more specifically ascertain the distribution and diversity of mutations in ald, along with mutations in alr, ddlA, and cycA, we characterized all promoter, nonsynonymous, and loss-of-function mutations in these four genes across all strains in our data set ( Table 3 and Supplementary Table 8 ). Mutations were most frequent in ald (25 strains), followed by alr (17 strains). Only seven strains were determined to have mutations in either ddlA or cycA; none of these mutations corresponded to previously characterized resistance-conferring mutations. We observed that many more strains had ald loss-offunction mutations than had ald nonsynonymous mutations (24 versus 5 strains, respectively). By contrast, mutations in alr were exclusively nonsynonymous, with the exception of one strain with a SNP in the promoter region, supporting the hypothesis that alr is essential 49 . 
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A r t i c l e s
We next sought to verify our prediction that clinical strains with ald loss-of-function mutations would exhibit resistance to d-cycloserine and to determine how that level of resistance compared to the resistance of strains with mutations in alr. We selected 44 clinical isolates from South Africa for testing, including 22 with wildtype ald and alr, 13 with mutations in ald and wild-type alr, 7 with wild-type ald and mutations in alr or its promoter, and 2 with mutations in both ald and alr (Supplementary Table 9 ). These strains had diverse drug susceptibility phenotypes and varying genetic backgrounds ( Supplementary Table 9 ).
Clinical isolates with ald mutations showed significantly greater resistance to d-cycloserine than strains with wild-type alleles of both ald and alr (P < 0.0002, Mann-Whitney U test; Fig. 5a and Supplementary Table 9 ). Strains with ald loss-of-function mutations had a median MIC of 40 µg/ml, with 8 of these 11 strains exhibiting an MIC of 30-40 µg/ml. The two strains with nonsynonymous SNPs in ald had MICs of 30 µg/ml; both of the nonsynonymous SNPs were predicted to have a deleterious effect on protein function by PROVEAN 50 (Supplementary Table 9) . By contrast, the strains with wild-type alleles for both genes had a median MIC of 20 µg/ml, with 91% of the strains exhibiting MICs ≤20 µg/ml. These data suggest that both deleterious nonsynonymous SNPs and loss-of-function mutations in ald can cause resistance to d-cycloserine in clinical isolates of M. tuberculosis, demonstrated by MICs at or above the current critical concentration for this drug (30 µg/ml; see URLs).
Clinical isolates with alr mutations also showed increased resistance to d-cycloserine relative to strains with wild-type alleles of both ald and alr ( Fig. 5a and Supplementary Table 9 ). Of the strains with nonsynonymous mutations in alr, four of six exhibited high-level resistance to d-cycloserine, with MICs of ≥60 µg/ml, whereas one of these strains, plus the two strains with both alr and ald mutations, exhibited an MIC of 40 µg/ml. As with ald, all of the nonsynonymous SNPs observed in alr were predicted to have a deleterious effect on protein function by PROVEAN 50 (Supplementary Table 9) . Additionally, the one strain with an alr promoter mutation showed high-level resistance (MIC >60 µg/ml), consistent with previous results in M. smegmatis that showed upregulation of alr through a promoter mutation that conferred resistance to d-cycloserine 19 . These results suggest that both nonsynonymous SNPs in the alr coding region and SNPs in its promoter can confer high-level resistance to d-cycloserine in clinical isolates of M. tuberculosis and that alr and ald mutations are non-additive for resistance.
DISCUSSION
To identify new drug-resistance-conferring mechanisms in M. tuberculosis, we analyzed whole-genome sequencing data for two large collections of clinical isolates from South Africa and China with diverse phenotypic drug resistance profiles. Combining a direct association test with a correlated evolution test, followed by functional screening of the top scoring genes with loss-of-function mutations, we identified a new drug resistance mechanism for d-cycloserine-ald loss of function-that we then validated experimentally. We further showed that clinical strains with mutations in ald and alr, identified through our computational analyses, were resistant to d-cycloserine. Collectively, this work expands the understanding of d-cycloserine resistance in M. tuberculosis and provides new opportunities to detect and manage d-cycloserine-resistant TB.
Strong linkage disequilibrium and the stratification present in bacterial populations have long been highlighted as a major hurdle for bacterial genome-wide association studies 51 . However, the problem of interdependence is not restricted to genotypes but extends to drug resistance phenotypes as well 26 . For most TB drugs, mutations known to confer resistance to a single drug were significantly associated with phenotypic resistance to numerous unrelated drugs. This is because TB is treated exclusively with multidrug regimens, which makes it difficult to collect clinical isolates of M. tuberculosis with The MIC for d-cycloserine was determined for each strain on LJ medium. Testing was carried out in three independent experiments (assays 1-3) to establish reproducibility.
Minus signs indicate strains that were not tested during a particular experiment. 25, 26 .
After we identified loss-of-function mutations in ald as a candidate drug resistance mechanism, we showed experimentally that ald loss of function confers resistance to d-cycloserine in M. tuberculosis. Complementation of the ald knockout strain with ald partially restored susceptibility to d-cycloserine (partial restoration by complementation has been observed before in M. tuberculosis and could be due to an altered expression level resulting from usage of a non-native promoter 52 ). We hypothesize that strains lacking functional Ald protein are unable to convert l-alanine to pyruvate, thereby increasing the pool of available l-alanine ( Fig. 3) . As l-alanine is the precursor to the pathway steps competitively inhibited by d-cycloserine, abundant l-alanine in the setting of non-functional Ald may allow for continued alanine racemization and d-alanine-d-alanine ligase activity and, therefore, continued peptidoglycan production despite competitive inhibition by d-cycloserine. However, the observation in clinical strains that ald loss of function conferred a lower level of resistance than nonsynonymous or promoter mutations in alr ( Supplementary  Table 9 ), which encodes the direct target of d-cycloserine, suggests that the resistance conferred by ald loss of function could more easily be overcome through increased dosage of d-cycloserine.
M. bovis and other members of the MTBC that lack RD9 (ref. 53 ) share a frameshift in ald. We sought to determine the effect of this frameshift in M. bovis strains traditionally classified as d-cycloserine resistant (BCG) and d-cycloserine susceptible (all other) 45 . We observed that the M. bovis reference strain, ATCC 19210, had elevated levels of d-cycloserine resistance in comparison to clinical isolates of M. tuberculosis lacking resistance-conferring mutations. Our results suggest that M. bovis and potentially the entire RD9 lineage, which is generally considered to be d-cycloserine susceptible, may actually have elevated resistance levels ( Fig. 5b; see URLs) . However, much of the RD9 lineage (including M. bovis but excluding BCG) also shares an inactivating mutation in the pykA gene encoding pyruvate kinase, which provides pyruvate to Ald 54,55 and, therefore, could potentially confound analysis of d-cycloserine resistance among these strains.
Evolutionary analyses suggest that, in animal-infecting species of the MTBC, there is more ancient functional diversity of these genes than in M. tuberculosis sensu stricto (Supplementary Fig. 3 and Supplementary Note). Future experiments to disentangle the roles of ald, pykA, and other related genes in drug resistance across the other species of the MTBC will be needed.
The identification of so many unique ald loss-of-function mutations among drug-resistant clinical strains of M. tuberculosis suggests that, despite conferring only a moderate level of resistance, this mechanism provides sufficient resistance to be selected for under current drug exposure pressures in South Africa (Supplementary Note). This further suggests that ald loss-of-function mutations might confer resistance to the d-cycloserine analog terizidone, which is routinely prescribed for treatment of drug-resistant M. tuberculosis in South Africa (see URLs), although this hypothesis still needs to be tested. Although ald loss of function may prove advantageous during exposure to d-cycloserine or terizidone, harboring such a mutation might prove to be deleterious in other settings. Strains with nonfunctional Ald may be unable to increase pyruvate availability under hypoxic conditions, and further laboratory investigation should determine whether ald loss of function results in decreased survival under hypoxia. However, when compared to the M. bovis genetic background where pykA is also non-functional, clinical M. tuberculosis strains with loss of function of ald may have greater ability to tolerate hypoxic environments (such as in a granuloma) where reliance on pyruvate (rather than aerobic metabolism) is greater.
Given the severe psychiatric and central nervous system toxicities of d-cycloserine 9,10,12 , it is critical to both incorporate d-cycloserine resistance mechanisms into molecular diagnostics and optimize phenotypic resistance assays to prevent the drug from being inappropriately prescribed to patients who harbor resistant strains. To maximize the effectiveness of phenotypic resistance assays, the range of wild-type MICs for an organism must be determined to define drug resistance and to set appropriate critical concentrations 56, 57 . Recently, the Stop TB Partnership recommended to the WHO that the critical concentration of d-cycloserine be lowered from 40 to 30 µg/ml (see URLs). Assuming that the two isolates exhibiting increased resistance to d-cycloserine but having wild-type alleles at both ald and alr harbor an unknown resistance mechanism, our results suggest a tentative epidemiological cutoff (ECOFF) 58 of 20 µg/ml (Fig. 5b) . Although phenotyping of a larger number of strains is required, our results support lowering the critical concentration below 30 µg/ml. Selection of a critical concentration would also need to consider whether it should be applied to M. tuberculosis sensu stricto or to the entire MTBC, including M. bovis. npg A r t i c l e s d-cycloserine resistance is an ideal target for molecular diagnostics, given technical difficulties with reproducibility and reliability for the phenotypic resistance assay [13] [14] [15] . However, current SNP-based diagnostics are not amenable to capturing loss-of-function mutations, as these mutations can occur anywhere within the gene and thus are difficult to capture with a small number of targeted SNPs. Other wholegene-based diagnostic strategies will instead need to be employed, some of which have already been developed for detection of drugresistant TB, such as high-resolution melt (HRM) analysis 59 and rapid whole-genome sequencing of clinical isolates 21 . Incorporation of resistance mechanisms to d-cycloserine and other highly toxic drugs into new molecular diagnostics could prevent these drugs from being prescribed in a treatment setting where they might be ineffective and needlessly toxic.
URLs. Hain Genotype MTBDRplus, http://www.hain-lifescience. de/en/products/microbiolog y/mycobacteria/tuberculosis/ genotype-mtbdrplus.html; Hain Genotype MTBDRsl, http://www. hain-lifescience.de/en/products/microbiology/mycobacteria/ tuberculosis/genotype-mtbdrsl.html; Picard, http://broadinstitute. github.io/picard; BayesTraits, http://www.evolution.rdg.ac.uk/ BayesTraits.html.
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